论文部分内容阅读
目的:对血清CA125、CA72-4、CA199单项检测及联合检测对诊断卵巢癌的临床价值进行探讨。方法:随机抽取了2010年1月—2013年6月进行血清CA125、CA72-4、CA199检验的就诊人员158例,其中包括卵巢良性病变患者49例,卵巢癌患者59例,正常人50例,通过电化学发光法对就诊人员进行CA125、CA72-4、CA199的检验,为卵巢癌的诊断提供科学的依据。结果:使用CA125、CA72-4、CA199三项联合的检测方式,大大提高了卵巢癌患者的确诊率,与单项检测存在着较大差异,具备统计学意义(P<0.05)。结论:对血清CA125、CA72-4、CA199进行三项联合的检测,有效提高了卵巢癌患者的诊断率,且能够发现亚临床阶段的卵巢癌患者和早期卵巢癌的病症,具有很大的意义,值得在临床上进行大范围的推广和应用。
Objective: To investigate the clinical value of single detection and combined detection of serum CA125, CA72-4 and CA199 in the diagnosis of ovarian cancer. Methods: A total of 158 patients with serum CA125, CA72-4 and CA199 tests from January 2010 to June 2013 were randomly selected, including 49 cases of benign ovarian disease, 59 cases of ovarian cancer, 50 cases of normal, Electrochemiluminescence method for the treatment of CA125, CA72-4, CA199 test for the diagnosis of ovarian cancer provide a scientific basis. Results: The detection rate of patients with ovarian cancer was greatly improved by the combination of CA125, CA72-4 and CA199, which was significantly different from the single test (P <0.05). Conclusion: The three combined detection of serum CA125, CA72-4 and CA199 can effectively improve the diagnosis rate of ovarian cancer patients, and can find the subclinical ovarian cancer patients and early ovarian cancer, has great significance , It is worth in the clinical large-scale promotion and application.